Pembrolizumab has shown significant benefits in extending survival and improving the quality of life for patients with various cancers. It has demonstrated efficacy in shrinking tumors and achieving lasting remissions, particularly in cancers with high PD-L1 expression. Additionally, pembrolizumab has fewer side effects compared to traditional chemotherapy.
